|View printer-friendly version|
United States Patent and Trademark Office Issues Composition of Matter Patent with BeyondSpring’s Lead Asset Plinabulin with Protection to 2036
This composition of matter patent is directed to Plinabulin’s monohydrate in a crystalline form and provides patent protection in the U.S. until 2036. Dr.
“Adding yet another vital patent to BeyondSpring’s robust global intellectual property (IP) portfolio enables us to effectively maximize Plinabulin’s commercial potential across therapeutic indications, starting with chemotherapy-induced neutropenia (CIN) prevention and non-small cell lung cancer (NSCLC) treatment, followed by combinations with immunotherapies,” said Dr. Huang. “This new patent provides additional protection for Plinabulin through 2036, further solidifying BeyondSpring’s position as a global leader in innovative drug development across the industry.”
Plinabulin is currently in two Phase 3 global clinical trials for the prevention of CIN and NSCLC treatment.
Cautionary Note Regarding Forward-Looking Statements